Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Imaging HER2 receptor binding in breast during the course of therapy with dual-agent fluorescence

EF 2010-11

Résumé
A major shift in our understanding of cancer came from the realization that physically similar tumors could respond in very different ways to the same treatment approaches. In response, a more personalized strategy for cancer therapy has been proposed, one that is coming into use in the treatment of breast cancer. It's now known that the aggressiveness of a breast cancer tumor and its resistance to chemotherapy is correlated with the tumor's level of expression of a particular molecular, human epidermal growth factor receptor 2 (HER2). The molecule is only found in abundance in cancerous tissue and is a key promoter of tumor growth. As such, new therapies have been developed to target HER2 expression by "molecular therapy". The success of these expensive therapies is strongly dependent on the level of HER2 expression, so it is important to only treat patients who would benefit most (those having tumors with high HER2 expression). Current methods of gauging the level of HER2 expression in a breast tumor only take a biopsy from a small section of the tumor and do not account for heterogeneous HER2 expression in the tumor or possible HER2 expression in secondary tumor sites. Therefore, to get a "full picture" of HER2 expression in the breast for guiding treatment, it is preferable to use molecular imaging approaches that are capable of non-invasively mapping HER2 expression. One problem with most of these approaches is they are unable to quantify the level of HER2 expression and often overestimate it. The purpose of the proposed research is to apply a dual-probe molecular imaging method to improve the accuracy of HER2 expression mapping. The approach involves injecting two probes together: one that binds to HER2 and one that does not. The uptake of both probes is imaged with fluorescence imaging (the only technique capable of resolving multiple probes), and a mathematical model is applied to map HER2 expression quantitatively assist breast cancer treatment planning.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
New Hampshire, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
226630
Name
Tichauer Kenneth M
Region
New Hampshire
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Imaging HER2 receptor binding in breast during the course of therapy with dual-agent fluorescence
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Breast Cancer; Her2 Receptor; Molecular Imaging; Tracer Kinetic Modeling
Abstract
A major shift in our understanding of cancer came from the realization that physically similar tumors could respond in very different ways to the same treatment approaches. In response, a more personalized strategy for cancer therapy has been proposed, one that is coming into use in the treatment of breast cancer. It's now known that the aggressiveness of a breast cancer tumor and its resistance to chemotherapy is correlated with the tumor's level of expression of a particular molecular, human epidermal growth factor receptor 2 (HER2). The molecule is only found in abundance in cancerous tissue and is a key promoter of tumor growth. As such, new therapies have been developed to target HER2 expression by "molecular therapy". The success of these expensive therapies is strongly dependent on the level of HER2 expression, so it is important to only treat patients who would benefit most (those having tumors with high HER2 expression). Current methods of gauging the level of HER2 expression in a breast tumor only take a biopsy from a small section of the tumor and do not account for heterogeneous HER2 expression in the tumor or possible HER2 expression in secondary tumor sites. Therefore, to get a "full picture" of HER2 expression in the breast for guiding treatment, it is preferable to use molecular imaging approaches that are capable of non-invasively mapping HER2 expression. One problem with most of these approaches is they are unable to quantify the level of HER2 expression and often overestimate it. The purpose of the proposed research is to apply a dual-probe molecular imaging method to improve the accuracy of HER2 expression mapping. The approach involves injecting two probes together: one that binds to HER2 and one that does not. The uptake of both probes is imaged with fluorescence imaging (the only technique capable of resolving multiple probes), and a mathematical model is applied to map HER2 expression quantitatively assist breast cancer treatment planning.
Competitiondate
201102
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tichauer, Kenneth M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~